BACKGROUND: Pathologic stage (pStage) IA and IB non-small-cell lung cancer (NSCLC) has a median survival time of 119 and 81 months, respectively. We describe the outcomes of veterans with pStage I NSCLC. METHODS: A retrospective review of 78 patients with pStage I NSCLC who underwent cancer resection was performed at the Tennessee Valley Veterans Affairs Hospital between 2005 and 2010. All-cause 30-day, 90-day, and overall mortality were determined. Survival was assessed with the Kaplan-Meier and Cox proportional hazards methods. RESULTS: There were 55 (71%) pStage IA and 23 (29%) IB patients. Thirty- and 90-day mortality was 3.8% (3 of 78) and 6.4% (5 of 78), respectively. Median survival was 59 and 28 months for pStage 1A and 1B, respectively. Postoperative events were associated with impaired survival on multivariable analysis (hazard ratio, 1.26, P = .03). CONCLUSIONS: Veterans with pStage I NSCLC at our institution have poorer survival than the general population. More research is needed to determine the etiology of this disparity. Published by Elsevier Inc.
BACKGROUND: Pathologic stage (pStage) IA and IB non-small-cell lung cancer (NSCLC) has a median survival time of 119 and 81 months, respectively. We describe the outcomes of veterans with pStage I NSCLC. METHODS: A retrospective review of 78 patients with pStage I NSCLC who underwent cancer resection was performed at the Tennessee Valley Veterans Affairs Hospital between 2005 and 2010. All-cause 30-day, 90-day, and overall mortality were determined. Survival was assessed with the Kaplan-Meier and Cox proportional hazards methods. RESULTS: There were 55 (71%) pStage IA and 23 (29%) IB patients. Thirty- and 90-day mortality was 3.8% (3 of 78) and 6.4% (5 of 78), respectively. Median survival was 59 and 28 months for pStage 1A and 1B, respectively. Postoperative events were associated with impaired survival on multivariable analysis (hazard ratio, 1.26, P = .03). CONCLUSIONS: Veterans with pStage I NSCLC at our institution have poorer survival than the general population. More research is needed to determine the etiology of this disparity. Published by Elsevier Inc.
Authors: Barbara G Campling; Wei-Ting Hwang; Jiameng Zhang; Stephanie Thompson; Leslie A Litzky; Anil Vachani; Ilene M Rosen; Kenneth M Algazy Journal: Cancer Date: 2005-08-15 Impact factor: 6.860
Authors: L E Kazis; D R Miller; J Clark; K Skinner; A Lee; W Rogers; A Spiro; S Payne; G Fincke; A Selim; M Linzer Journal: Arch Intern Med Date: 1998-03-23
Authors: Kari Chansky; Jean-Paul Sculier; John J Crowley; Dori Giroux; Jan Van Meerbeeck; Peter Goldstraw Journal: J Thorac Oncol Date: 2009-07 Impact factor: 15.609
Authors: Mark S Allen; Gail E Darling; Taine T V Pechet; John D Mitchell; James E Herndon; Rodney J Landreneau; Richard I Inculet; David R Jones; Bryan F Meyers; David H Harpole; Joe B Putnam; Valerie W Rusch Journal: Ann Thorac Surg Date: 2006-03 Impact factor: 4.330
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Amelia W Maiga; Stephen A Deppen; Jason Denton; Michael E Matheny; Erin A Gillaspie; Jonathan C Nesbitt; Eric L Grogan Journal: JAMA Surg Date: 2019-06-01 Impact factor: 14.766